SOURCE: CZ BioMed Corp.

May 03, 2011 11:24 ET

Breast Cancer Cure International Patent Application # PCT/US2011/000602 CZ BioMed Corp.

TAMPA, FL--(Marketwire - May 3, 2011) - CZ BioMed Corp. announced today they have successfully applied for an international patent for its new treatment for breast cancer, BRVLYSIN, a novel oncolytic virotherapy which is a new class of potent, genetically engineered, common-cold-like virus, that selectively kills breast cancer cells, but not normal healthy cells. This medical breakthrough will allow CZ BioMed to potentially help millions of people worldwide in their battle against cancer. Additional patents are being drafted as of this writing, with global technology protection anticipated.

As a result of this milestone, CZ BioMed Corp. will now open aggressive discussions with all interested global bio-pharma leaders, for partnership arrangements and licensing of the technologies. Simultaneously, the company will begin IND (Investigational-New-Drug) filings with the United States FDA to initiate Phase 1 clinical trials. If your company is interested in licensing these technologies, please contact info@czbiomed.com for further details.

BRVLYSIN is the invention of CZ BioMed Corp. BRVLYSIN is a genetically modified oncolytic virus that selectively targets and destroys breast cancer cells, whilst leaving surrounding non-malignant cells unharmed. The destruction of these cancer cells occurs either through direct lytic rupture via multiple cycles of viral replication or the subsequent induction of apoptosis, also known as programmed cell death. Thus, BRVLYSIN is vastly safer to use and easier for the body to process, as compared to traditional chemo -- or radio-therapies of tumors, allowing patients to enjoy a much higher quality of life during treatment.

BRVLYSIN preferentially kills breast cancer cells both in vitro and in vivo. MDA-MB-231 breast cancer cells and normal CCD-1059SK (Human normal breast fibroblast) were cultured as indicated by ATCC (American Type Culture Collection) instructions, and then infected with the wild type and BRVLYSIN (MOI=5) versions of the virus respectively. BRVLYSIN selectively induced cytopathic effect (CPE) in the MDA-MB-231 breast cancer cells, and had a higher viral titer in these tumor cells than in the normal CCD-1059SK cells 24h post-infection.

BRVLYSIN was also found to kill T-47D cells, a p53- cell like the subject MDA-MB-231's, as well as p53+ breast cancer cells such as MCF7. This indicates that BRVLYSIN has the potential to treat a very broad spectrum of breast cancers.

Moreover, BRVLYSIN induced less neutralizing antibodies upon in vivo administration because of its lower antigenesis as compared to other oncolytic viruses. This suggests that BRVLYSIN can be administered multiple times to allow for maximum effect in eradicating the tumor, without concern for the host body rejecting it or fighting off the treatment.

In an established human breast cancer nude BALB/c mouse model, BRVLYSIN was locally injected into the tumors three times and the sizes of the tumors were significantly reduced by day 8 versus controls. At day 18 post- BRVLYSIN -injection, the sizes of the tumors almost disappeared and have not shown signs of restoration since.

BRVLYSIN specifically localizes to the tumor upon direct injection, and does not spread to other tissues or organs. Thus, this procedure is not harming areas of the body that are not currently in danger of the cancer. Intravenous administration for distant cancers is also possible with its use as a pre-cancer vaccination highly plausible at this point due to the virus' ability to exist, and not infect non-cancerous cells.

Breast cancer is the most common cancer among women, with more than one million new cases identified worldwide each year. An estimated 192,370 patients were newly diagnosed with breast cancer in the United States alone in 2009, and about 40,170 died of the disease. Approximately 24% to 30% of women who have no lymph-node involvement at the time of diagnosis will relapse; the relapse rate for node-positive women is between 50%-60%. The 5-year survival rates for those diagnosed with regional and metastatic disease are 80% and 26%, respectively. Therefore, a safe and effective treatment remains a critical need.

"We are very excited to reach this milestone today. These patents usher in a new era of internationally viable therapies and cooperation between nations to finally eliminate cancer and their current, destructive treatments.BRVLYSIN is the first of many treatments to be brought to light."
~
Calvin Cao, Chairman / CEO / President of CZ BioMed Corp.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of CZ BioMed Corp. is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

Contact Information

  • FOR FURTHER INFORMATION
    CONTACT:
    CZ BioMed Corp.
    info@czbiomed.com
    Phone: 813-600-4088